Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry

European Journal of Nuclear Medicine

Volumn 23, Issue 12, 1996, Pages 1588-1593

  Utech, Christa I ^a,c   Young, Carter S ^b   Winter, Peter F ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Methodist Medical Center of Illinois   (United States)

^c NONE   (Germany)

Author keywords

Axillary lymph nodes; Breast tumors; Fluorine 18 fluoro 2 deoxy D glucose; Positron emission tomography

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SCINTISCANNING; CANCER STAGING; CELL CYCLE S PHASE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PLOIDY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; TUMOR VOLUME;

AXILLA; BREAST NEOPLASMS; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030476914     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01249621     Document Type: Article

References (28)

1. Boring CC, Suires TS, Tong T. Cancer Statistics 1993. CA Cancer J Clin 1993; 43: 7-26.
2. Berg JW, Hutter RVP. Breast cancer. Cancer 1995; 75: 257-269.
3. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK. Cancer statistics review 1973-91: tables and graphs. National Institutes of Health Publication no. 94-2798, Bethesda, Md: National Cancer Institute, 1994.
4. Anderson I, Aspegren K, Janzon I, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfusson B. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. Br Med J 1988; 297: 943-948.
5. Warburg O. The metabolism of tumors. London; Constable; 1938; 254-270.
6. Brownell G, Sweet H. Localization of brain tumors with positron emitters. Nucleonics 1953; 11: 40-45.
7. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP. Glucose utilization of cerebral gliomas measured by (18)fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329.
8. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, Marin-Grez M, Helus F, Oberdorfer F, Schmidlin P, van Kaick G. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329-332.
9. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-F-18-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-770.
10. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
11. Nieweg OE, Kim KE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
12. Nieweg OE, Wong WH, Singletary SE, Hortobagyi GN, Kim EE. Positron emission tomography of glucose metabolism in breast cancer. Ann NY Acad Sci 1993; 698: 423-428.
13. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
14. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurement for evaluating 2-F18-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995; 196: 167-173.
15. Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, Ohshio G, Imamura M, Konishi J. Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 1995; 36: 229-235.
16. Braams JW, Pruim J, Freling NJM, Nikkels PGJ, Rodenburg JLN, Boering G, Vaalburg W, Vermey A. Detection of lymph node metastases of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36: 211-216.
17. Gupta N, Chandramouli B, Reeb S, Dewan N. Diagnostic evaluation of solitary pulmonary nodules (SPNs) using PET-FDG imaging. J Nucl Med 1994; 35 Suppl 5: 76.
18. Grabbe E, Winkler R. Local recurrence after sphincter-saving resection for rectal and rectosigmoid carcinoma: value of various diagnostic methods. Radiology 1995; 155: 305-310.
19. Holle LH, Trampert L, Lung-Kurt S, Villena-Heinsen CE, Püschel W, Schmidt S, Oberhausen E. Investigation of breast tumors with fluorine-18-fluorodeoxyglucose and SPECT. J Nucl Med 1996; 37: 615-622.
20. Hermanek P, Henson DE, Hutter RVP, eds. UICC complement the 4th edition of the TNM classification of malignant tumors. TNM supplement 1993: a commentary on uniform use. Berlin Heidelberg New York: Springer, 1993.
21. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34: 1-6.
22. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-fluorine-18-fluoro-2-deoxy-D-glucose: variations with body weight and method for correction. Radiology 1993; 189: 874-850.
23. Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M, Tse NY, Hoffman EJ, Schiepers C, Choi Y, Rege S, Nitsche E, Phelps ME. Cancer detection with whole-body PET using 2-18-F-fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-589.
24. Sigurdsson H, Baldetorp B, Borg A, Dalherg M, Fernö M, Killander D, Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045-1053.
25. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992; 326: 1756-1761.
26. Clark GM, Wenger CR, Beardslee BA, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, McGuire WL. How to integrate steroid hormone receptor, flow cytometry, and other prognostic information in regard to primary breast cancer. Cancer 1993; 71: 2157-2162.
27. Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S, Koyama H. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 1994; 74: 1595-1600.
28. Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or "skip" metastases in breast carcinoma: analysis of 1228 axillary dissections. Ann Surg 1982; 197: 276-283.